Chronic Prurigo Guideline
September 2022
The U.S. Food and Drug Administration (FDA) has approved Dupilumab for the treatment of adults with chronic nodular prurigo (syn.: prurigo nodularis). This is an important milestone, as this is the first FDA approved treatment for chronic nodular prurigo.
You can read the press release here:
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-prurigo-nodularis
December 2020 The first international Guideline on Chronic Prurigo and Prurigo nodularis has now been published at the journal ITCH and is available here: https://journals.lww.com/itch/Fulltext/2020/10010/IFSI_guideline_on_chronic_prurigo_including.1.aspx September 23nd, 2020 We are pleased to announce that the first Guideline on Chronic Prurigo including Prurigo Nodularis has been accepted for publication at the journal ITCH today. The article will be available soon. This guideline was developed by European and American authors, all members of the International Forum for the Study of Itch (IFSI). April 2020 After the consensus meeting in August 2019, the international group of experts working on the guideline have completed post-meeting surveys to vote upon open issues related to the guideline. The guideline will now be finalized and submitted for publication in a specialty journal. 
|
August 30th, 2019:
At their last meeting on August 30th, 2019, an international group of experts began working on creating the first international, evidence and expert-based guideline for chronic prurigo. Its topics include the epidemiology, definition, terminology, pathophysiology, severity and burden of chronic prurigo, next to exact diagnostics, and therapy of this disease. Members of the group met last August for a consensus conference.
At their last meeting on August 30th, 2019, an international group of experts began working on creating the first international, evidence and expert-based guideline for chronic prurigo. Its topics include the epidemiology, definition, terminology, pathophysiology, severity and burden of chronic prurigo, next to exact diagnostics, and therapy of this disease. Members of the group met last August for a consensus conference.
|
July 31st, 2019:
The recruitment phase of the cross-sectional EPP study taking place in 15 centers across 12 European countries has been successfully concluded. Over 500 patients were enrolled. Data is currently being analyzed and the results are expected to be published soon. Click here and here to read the resulting papers. |